P131: Persistence of growth-promoting effects in infants and toddlers with achondroplasia: Results from a phase II extension study with vosoritide*

• Ravi Savarirayan,
• William Wilcox,
• Paul Harmatz,
• John Phillips, III,
• Lynda Polgreen,
• Louise Tofts,
• Keiichi Ozono,
• Paul Arundel,
• Melita Irving,
• Carlos Bacino,
• Donald Basel,
• Ricki Carroll,
• Joel Charrow,
• Hiroshi Mochizuki,
• Yumiko Kotani,
• Howard Saal,
• Lingling Han,
• Andrea Low,
• Elena Fisheleva,
• Jonathan Day

Affiliations

Ravi Savarirayan

Murdoch Children’s Research Institute, Royal Children’s Hospital, and University of Melbourne, Parkville, Victoria, Australia

William Wilcox

Department of Human Genetics, Emory University, Atlanta, GA

Paul Harmatz

UCSF Benioff Children’s Hospital Oakland, CA

John Phillips, III

Vanderbilt University Medical Center, Nashville, TN

Lynda Polgreen

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA; Kids Rehab

Louise Tofts

The Children's Hospital at Westmead, Westmead, New South Wales, Australia

Keiichi Ozono

Osaka University Hospital, Osaka, Japan

Paul Arundel

Sheffield Children's NHS Foundation Trust, Sheffield Children's Hospital, Sheffield, UK

Melita Irving

Guy’s and St. Thomas’ NHS Foundation Trust, Evelina Children's Hospital, London, UK

Carlos Bacino

Baylor College of Medicine, Houston, TX

Donald Basel

Medical College of Wisconsin, Milwaukee, WI

Ricki Carroll

Nemours/Alfred I. du Pont Hospital for Children, Wilmington, DE

Joel Charrow

Ann and Robert H. Lurie Children’s Hospital of Chicago, IL

Hiroshi Mochizuki

Saitama Children’s Hospital, Saitama, Japan

Yumiko Kotani

Tokushima University Hospital, Tokushima, Japan

Howard Saal

Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, OH

Lingling Han

BioMarin Pharmaceutical Inc., Novato, CA

Andrea Low

BioMarin (U.K.) Limited, London, UK

Elena Fisheleva

BioMarin (U.K.) Limited, London, UK

Jonathan Day

BioMarin (U.K.) Limited, London, UK